Aurelian Amiot

List of Publications by Year
in descending order

101 papers	2,862 citations	172386 29 h-index	189801 50 g-index
103 all docs	103 docs citations	103 times ranked	3545 citing authors

#	Article	IF	Citations
1	Determinants of home parenteral nutrition dependence and survival of 268 patients with non-malignant short bowel syndrome. Clinical Nutrition, 2013, 32, 368-374.	2.3	186
2	Effectiveness and Safety of Vedolizumab Induction Therapy forÂPatients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2016, 14, 1593-1601.e2.	2.4	168
3	Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohnâ€™s Disease Refractory to Antiâ€“Tumor Necrosis Factor Agents. Clinical Gastroenterology and Hepatology, 2016, 14, 242-250.e2.	2.4	155
4	Oneâ€year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Alimentary Pharmacology and Therapeutics, 2017, 46, 310-321.	1.9	128
5	Microbial dysbiosis and colon carcinogenesis: could colon cancer be considered a bacteria-related disease?. Therapeutic Advances in Gastroenterology, 2013, 6, 215-229.	1.4	120
6	Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut, 2018, 67, 237-243.	6.1	119
7	Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therapeutic Advances in Gastroenterology, 2015, 8, 66-82.	1.4	115
8	Long-Term Outcome of Chronic Intestinal Pseudo-Obstruction Adult Patients Requiring Home Parenteral Nutrition. American Journal of Gastroenterology, 2009, 104, 1262-1270.	0.2	102
9	Impact of vedolizumab therapy on extraâ€intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the <scp>OBSERV</scp>â€<scp>IBD</scp> cohort. Alimentary Pharmacology and Therapeutics, 2018, 47, 485-493.	1.9	91
10	The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to antiâ€tumour necrosis factor. Alimentary Pharmacology and Therapeutics, 2020, 51, 948-957.	1.9	84
11	Longâ€term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience. Alimentary Pharmacology and Therapeutics, 2018, 47, 588-595.	1.9	73
12	Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohnâ€™s Disease in Sustained Remission. Clinical Gastroenterology and Hepatology, 2018, 16, 234-243.e2.	2.4	71
13	Frequency of Mitochondrial Defects in Patients With Chronic Intestinal Pseudo-Obstruction. Gastroenterology, 2009, 137, 101-109.	0.6	64
14	Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre realâ€world cohort study. Alimentary Pharmacology and Therapeutics, 2020, 51, 1039-1046.	1.9	54
15	Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort. Journal of Crohn's and Colitis, 2016, 10, 1179-1185.	0.6	53
16	2017 WSES guidelines for the management of iatrogenic colonoscopy perforation. World Journal of Emergency Surgery, 2018, 13, 5.	2.1	53
17	Features of Autoimmune Pancreatitis Associated With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2018, 16, 59-67.	2.4	52
18	Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID. American Journal of Gastroenterology, 2020, 115, 1812-1820.	0.2	50

#	Article	IF	Citations
19	Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. Digestive and Liver Disease, 2020, 52, 268-273.	0.4	49
20	Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study. Alimentary Pharmacology and Therapeutics, 2021, 53, 460-470.	1.9	49
21	Threeâ€year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multiâ€centre cohort study. Alimentary Pharmacology and Therapeutics, 2019, 50, 40-53.	1.9	46
22	Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Scientific Reports, 2022, 12, 7140.	1.6	45
23	The Detection of the Methylated Wif-1 Gene Is More Accurate than a Fecal Occult Blood Test for Colorectal Cancer Screening. PLoS ONE, 2014, 9, e99233.	1.1	42
24	Rescue therapy with bismuth-containing quadruple therapy in patients infected with metronidazole-resistant Helicobacter pylori strains. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 517-524.	0.7	41
25	Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort Study. Journal of Crohn's and Colitis, 2019, 13, 1239-1247.	0.6	38
26	Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 90-98.	0.7	35
27	Risk of Rectal Neoplasia after Colectomy and Ileorectal Anastomosis for Ulcerative Colitis. Journal of Crohn's and Colitis, 2017, 11, 930-935.	0.6	34
28	Prognostic yield of esophageal manometry in chronic intestinal pseudoâ€obstruction: a retrospective cohort of 116 adult patients. Neurogastroenterology and Motility, 2012, 24, 1008.	1.6	33
29	Laparoscopic vs. open surgery for the treatment of iatrogenic colonoscopic perforations: a systematic review and meta-analysis. World Journal of Emergency Surgery, 2017, 12, 8.	2.1	32
30	Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: A retrospective study. Digestive and Liver Disease, 2014, 46, 695-700.	0.4	31
31	A clinical decision support tool may help to optimise vedolizumab therapy in Crohnâ€™s disease. Alimentary Pharmacology and Therapeutics, 2020, 51, 553-564.	1.9	30
32	Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational study. Leukemia and Lymphoma, 2013, 54, 940-944.	0.6	29
33	Efficacy of a tailored PCR-guided triple therapy in the treatment of Helicobacter pylori infection. MÃ©decine Et Maladies Infectieuses, 2020, 50, 492-499.	5.1	28
34	Autoimmune cytopenias associated with inflammatory bowel diseases: Insights from a multicenter retrospective cohort. Digestive and Liver Disease, 2017, 49, 397-404.	0.4	27
35	A Scoring System to Determine Patientsâ€™ Risk of Colectomy Within 1 Year After Hospital Admission for Acute Severe Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1602-1610.e1.	2.4	26
36	Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study. Alimentary Pharmacology and Therapeutics, 2021, 54, 944-951.	1.9	24

#	Article	IF	Citations
37	Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study. Alimentary Pharmacology and Therapeutics, 2017, 46, 1077-1084.	1.9	23
38	Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis. Clinical Gastroenterology and Hepatology, 2020, 18, 620-627.e1.	2.4	21
39	Long-term outcome after extensive intestinal resection for chronic radiation enteritis. Digestive and Liver Disease, 2013, 45, 110-114.	0.4	19
40	Rituximab, alkylating agents or combination therapy for gastric mucosaâ€associated lymphoid tissue lymphoma: a monocentric nonâ€randomised observational study. Alimentary Pharmacology and Therapeutics, 2014, 39, 619-628.	1.9	19
41	Longâ€term outcome of patients with acute severe ulcerative colitis responding to intravenous steroids. Alimentary Pharmacology and Therapeutics, 2020, 51, 1096-1104.	1.9	19
42	Outcomes after double switching from originator Infliximab to biosimilar CTâ€P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12â€month prospective cohort study. Alimentary Pharmacology and Therapeutics, 2021, 53, 887-899.	1.9	19
43	The outcome of infliximab dose doubling in 157 patients with ulcerative colitis after loss of response to infliximab. Alimentary Pharmacology and Therapeutics, 2015, 42, 1192-1199.	1.9	18
44	Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases. Expert Opinion on Biological Therapy, 2019, 19, 1001-1014.	1.4	18
45	Efficacy, Tolerability, and Safety of Low-Volume Bowel Preparations for Patients with Inflammatory Bowel Diseases: The French Multicentre CLEAN Study. Journal of Crohn's and Colitis, 2019, 13, 1121-1130.	0.6	16
46	Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensus. Digestive and Liver Disease, 2021, 53, 35-43.	0.4	16
47	Prediction of Relapse After Antiâ€“Tumor Necrosis Factor Cessation in Crohnâ€™s Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies. Clinical Gastroenterology and Hepatology, 2022, 20, 1671-1686.e16.	2.4	15
48	Sporadic desmoid tumor. An exceptional cause of cystic pancreatic lesion. JOP: Journal of the Pancreas, 2008, 9, 339-45.	1.5	15
49	Dose de-escalation to adalimumab 40â€mg every three weeks in patients with inflammatory bowel diseaseâ€”A multicenter, retrospective, observational study. Digestive and Liver Disease, 2019, 51, 236-241.	0.4	14
50	Long-term course of precancerous lesions arising in patients with gastric MALT lymphoma. Digestive and Liver Disease, 2018, 50, 181-188.	0.4	13
51	The outcome of Crohn's disease patients refractory to anti-TNF and either vedolizumab or ustekinumab. Digestive and Liver Disease, 2020, 52, 1148-1155.	0.4	13
52	Comparative Acceptability of Therapeutic Maintenance Regimens in Patients With Inflammatory Bowel Disease: Results From the Nationwide ACCEPT2 Study. Inflammatory Bowel Diseases, 2023, 29, 579-588.	0.9	13
53	Efficacy and Safety of Tumor Necrosis Factor Antagonists in Treatment of Internal Fistulizing Crohn's Disease. Clinical Gastroenterology and Hepatology, 2020, 18, 628-636.	2.4	12
54	Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study. Journal of Crohn's and Colitis, 2020, 14, 896-903.	0.6	12

#	Article	IF	Citations
55	Impact of HIV Infection on the Course of Inflammatory Bowel Disease and Drug Safety Profile: A Multicenter GETAID Study. Clinical Gastroenterology and Hepatology, 2022, 20, 787-797.e2.	2.4	11
56	The IBD-disk Is a Reliable Tool to Assess the Daily-life Burden of Patients with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2021, 15, 766-773.	0.6	11
57	Second primary malignancies in patients treated for gastric mucosa-associated lymphoid tissue lymphoma. Leukemia and Lymphoma, 2017, 58, 2057-2064.	0.6	10
58	Rate and Predictors of Mucosal Healing in Ulcerative Colitis Treated with Thiopurines: Results of a Multicentric Cohort Study. Digestive Diseases and Sciences, 2017, 62, 473-480.	1.1	10
59	Risk of serious infection in healthcare workers with inflammatory bowel disease: a caseâ€control study of the Groupe d'Etude ThÃ©rapeutique des Affections Inflammatoires du tube Digestif (GETAID). Alimentary Pharmacology and Therapeutics, 2018, 48, 713-722.	1.9	10
60	Kidney function monitoring in inflammatory bowel disease: The MONITORED consensus. Digestive and Liver Disease, 2022, 54, 309-315.	0.4	10
61	Patientsâ€™ perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study. Digestive and Liver Disease, 2019, 51, 1652-1660.	0.4	9
62	Colonic mucosa-associated lymphoid tissue lymphoma: a case series. Leukemia and Lymphoma, 2020, 61, 582-587.	0.6	9
63	Determinants of IBDâ€related disability: a crossâ€sectional survey from the GETAID. Alimentary Pharmacology and Therapeutics, 2021, 53, 1098-1107.	1.9	9
64	Predictors of mortality following emergency open colectomy for ischemic colitis: a single-center experience. World Journal of Emergency Surgery, 2020, 15, 40.	2.1	8
65	Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study. Scandinavian Journal of Gastroenterology, 2022, 57, 1454-1462.	0.6	8
66	Experience with the use of a hemostatic powder in 152 patients undergoing urgent endoscopy for gastrointestinal bleeding. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101558.	0.7	6
67	Impact of abdominal or pelvic radiotherapy on disease activity in inflammatory bowel disease: a multicentre cohort study from the GETAID. Alimentary Pharmacology and Therapeutics, 2021, 53, 400-409.	1.9	6
68	Paradoxical reactions and biologic agents: a French cohort study of 9303 patients. British Journal of Dermatology, 2022, 187, 676-683.	1.4	6
69	Management of immune checkpoint inhibitor in patients with cancer and pre-existing inflammatory bowel disease: Recommendations from the GETAID. Digestive and Liver Disease, 2022, 54, 1162-1167.	0.4	6
70	P248 Validation of IBD-disk for the assessment of daily-life burden of patients with inflammatory bowel disease. Journal of Crohn's and Colitis, 2020, 14, S272-S272.	0.6	5
71	Letter: severe COVIDâ€19 infection and biologic therapiesâ€”a cohort study of 7 808 patients in France. Alimentary Pharmacology and Therapeutics, 2020, 52, 1245-1248.	1.9	5
72	The impact of COVID-19 on patients with IBD in a prospective European cohort study. Journal of Crohn's and Colitis, 0, , .	0.6	5

#	Article	IF	Citations
73	P528 Patientsâ€™ perspectives on switching from reference infliximab to CT-P13 biosimilar in patients with inflammatory bowel disease: A 12-month prospective observational cohort study. Journal of Crohn's and Colitis, 2018, 12, S373-S374.	0.6	4
74	Real-world use of therapeutic drug monitoring of CT-P13 in patients with inflammatory bowel disease: A 12-month prospective observational cohort study. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 609-618.	0.7	4
75	Effectiveness and Safety of Subcutaneous Rituximab for Patients With Gastric MALT Lymphoma: A Caseâ€“Control Comparison With Intravenous Rituximab. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e32-e38.	0.2	4
76	Patientsâ€™ comorbidities reduce the clinical value of emergency colonoscopy: results of a retrospective cohort study. Endoscopy International Open, 2017, 05, E1119-E1127.	0.9	3
77	P715 Real-world tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. Journal of Crohn's and Colitis, 2019, 13, S478-S479.	0.6	3
78	Long-term outcome of Crohn's disease patients with upper gastrointestinal stricture: A GETAID study. Digestive and Liver Disease, 2020, 52, 1323-1330.	0.4	3
79	Upper gastrointestinal obstruction due to trichobezoar. Presse Medicale, 2014, 43, 1008-1009.	0.8	2
80	Antiâ€‹<scp>TNF</scp> therapy for genital fistulas in female patients with Crohn's disease: a nationwide study from the Groupe d'Etude ThÃ©rapeutique des Affections Inflammatoires du tube Digestif (GETAID). Alimentary Pharmacology and Therapeutics, 2018, 48, 831-838.	1.9	2
81	Describing mode of death in three major cardiac amyloidosis subtypes to improve management and survival. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 79-91.	1.4	2
82	Tu1137 Hemophagocytic Syndrome During Inflammatory Bowel Disease (IBD): A Serious and Unfamiliar Complication of Immunosuppressive Therapy. Gastroenterology, 2013, 144, S-771-S-772.	0.6	1
83	Endoscopic training: A nationwide survey of French fellows in gastroenterology. Clinics and Research in Hepatology and Gastroenterology, 2018, 42, 160-167.	0.7	1
84	Letter: immunogenicity of infliximabâ€”ready for routine prediction?. Alimentary Pharmacology and Therapeutics, 2020, 51, 812-812.	1.9	1
85	Patientsâ€™ real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group. Digestive and Liver Disease, 2021, 53, 434-441.	0.4	1
86	Editorial: determining disability in inflammatory bowel diseaseâ€”â€œSee(k) and you shall findâ€•. Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 1323-1323.	1.9	1
87	How to Manage Inflammatory Bowel Disease Patients When They Withdraw Anti-Tumour Necrosis Factor [Anti-TNF] Due to Severe Anti-TNF-Induced Skin Lesions? A Multicentre Cohort Study. Journal of Crohn's and Colitis, 2022, 16, 1202-1210.	0.6	1
88	Prevalence of Self-Reported Venous Thromboembolism and Cardiovascular Risk Factors in Patients with Ulcerative Colitis: The GETAID FOCUS Study. Digestive Diseases and Sciences, 2022, , 1.	1.1	1
89	Rituximab or rituximab plus chlorambucil for translocation (11;18)-negative gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomized observational study. Leukemia and Lymphoma, 2022, 63, 2597-2603.	0.6	1
90	Urgences digestives. AnesthÃ©sie & RÃ©animation, 2015, 1, S17-S21.	0.1	0

#	Article	IF	Citations
91	Editorial: what can be done when infliximab stops working in ulcerative colitis? Authors' reply. Alimentary Pharmacology and Therapeutics, 2016, 43, 165-165.	1.9	0
92	P593 Efficacy, tolerance and safety of low-volume bowel preparations in inflammatory bowel diseases: Results from a French national multicentre study. Journal of Crohn's and Colitis, 2018, 12, S408-S408.	0.6	0
93	Choleperitoneum Fistula Associated with Ampullary Carcinoma: Case Report. SN Comprehensive Clinical Medicine, 2020, 2, 833-835.	0.3	0
94	Letter: new insights on tofacitinib dose deâ€escalation. Alimentary Pharmacology and Therapeutics, 2020, 51, 578-578.	1.9	0
95	Editorial: a long way to go before precision medicine. Alimentary Pharmacology and Therapeutics, 2021, 54, 187-187.	1.9	0
96	ENDOSCOPIC TRAINING DURING FELLOWSHIP: A NATIONWIDE FRENCH STUDY. Clinics and Research in Hepatology and Gastroenterology, 2021, 46, 101837.	0.7	0
97	P140 Immunomodulators are protective against severe COVID 19: results from a large multicentre cohort of inflammatory bowel disease patients. Journal of Crohn's and Colitis, 2022, 16, i222-i223.	0.6	0
98	P558 Should we introduce early a new biological agent in patients with Inflammatory Bowel Disease after anti-TNF discontinuation due to severe anti-TNF-induced skin lesions? A multicenter cohort study. Journal of Crohn's and Colitis, 2022, 16, i502-i503.	0.6	0
99	DOP76 Real-world multicenter comparison of effectiveness between tofacitinib and vedolizumab in patients with Ulcerative Colitis after failure to at least one anti-TNF agent. Journal of Crohn's and Colitis, 2022, 16, i120-i120.	0.6	0
100	Letter: longâ€term outcomes of patients with acute severe ulcerative colitis after intravenous steroid therapyâ€"authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 1252-1252.	1.9	0
101	Prevalence of anti-TNF contraindications in Crohn's disease: A cross-sectional survey from the GETAID. Digestive and Liver Disease, 2022, 54, 1350-1357.	0.4	0